Efgartigimod Shows Promise in Autoimmune Myositis Phase 3 Study

Argencx SE has announced promising results from its Phase 3 ALKIVIA study, which is the first global investigation of an FcRn blocker targeting autoimmune myositis. The study highlights that efgartigimod offers significant clinical improvements for patients suffering from immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM).

Key Study Findings

The ALKIVIA trial revealed that patients using efgartigimod experienced notable enhancements in their conditions as soon as Week 4 and maintained these benefits throughout the 52-week treatment period.

Presented as a late-breaking oral session during the American College of Rheumatology (ACR) Convergence 2026 on November 11, the study sets a new benchmark in the treatment of autoimmune myositis.

Clinically Relevant Outcomes

The Phase 3 study successfully met its primary endpoint by achieving a 15.4-point greater improvement in the mean Total Improvement Score (TIS) when compared to a placebo group. The final scores were 47.95 versus 32.56, respectively, with a statistical significance of p=0.0011.

Patients treated with efgartigimod demonstrated early improvements in disease activity, showing results as early as Week 4. This sustained improvement was observed even during the tapering of corticosteroid treatments.

• A significant number of patients with both IMNM and DM achieved a TIS of 40 or greater when treated with the medication, indicating meaningful progress.
• The median time to reach this threshold was shorter for those receiving efgartigimod compared to the placebo group.
• The treatment was well-tolerated, with a safety profile aligning with earlier studies.

The ALKIVIA Study Overview

The ALKIVIA trial was a comprehensive global effort that included 265 patients suffering from active autoimmune myositis. This randomized, double-blind, placebo-controlled trial aimed to assess the effects of efgartigimod given subcutaneously in comparison with a placebo.

Patients received weekly injections over the course of the study, with a close examination of clinical data after the initial 89 participants completed Phase 2, followed by the remaining 176 patients in Phase 3. The focus was on understanding the treatment effects over a full year.

Understanding Autoimmune Myositis

Autoimmune myositis is a complex and diverse disease characterized by chronic inflammation and muscle weakness, sometimes accompanied by skin lesions and other symptoms. In the United States, approximately 100,000 individuals are affected by this condition, with around 20,000 cases of IMNM and 40,000 cases of DM.

Despite treatment options, many patients experience long-term disabilities, primarily due to the limitations of current therapies, which predominantly rely on corticosteroids and nonspecific immunosuppressants. These treatments often lead to significant side effects, including metabolic and cardiovascular complications.

Potential of Efgartigimod

Efgartigimod (efgartigimod alfa fcab) is a uniquely designed human IgG1 antibody fragment known for its ability to target neonatal Fc receptor (FcRn). By doing so, it effectively reduces circulating IgG autoantibodies. This mechanism has previously established its efficacy in treating conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy globally.

The current findings from the ALKIVIA study aim to reshape the therapeutic landscape for autoimmune myositis and underline argenx's commitment to advancing unique treatment strategies for patients with limited options.

In summary, the results from this Phase 3 study constitute a significant breakthrough for individuals diagnosed with autoimmune myositis, shedding light on new avenues for effective treatment.